Nordic Nanovector To Present Clinical Data from Phase I/II Trial on Betalutin™ at Upcoming American Society of Hematology (ASH) Meeting

OSLO, Norway--()--Nordic Nanovector ASA (“Nordic Nanovector” or “the Company”) today announced that data from Betalutin’s Phase I/II trial will be presented in a poster session at the American Society of Hematology (ASH) 2014 Annual Meeting (December 6-9) in San Francisco. The poster reports the preliminary efficacy and safety data of patients with relapsed NHL enrolled in a 3+3 dose escalation Phase I study testing 3 different dose levels of Betalutin™. “We are looking forward to presenting the clinical results for Betalutin, the first radioimmunotherapeutic solution targeting CD-37 receptors on lymphoma cells that, thanks to its unique multi-cell kill approach, can deliver a robust clinical activity with a predictable safety profile,“ said Nordic Nanovector CEO, Luigi Costa.

The data is published on the ASH website at: http://www.hematology.org/Annual-Meeting/

Details

  • Program: Oral and poster abstracts
  • Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
  • Title: 3094 A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma
  • Date: Sunday, December 7, 2014
  • Time: 6:00 PM – 8:00 PM PST
  • Location: West Building, Level 1 (Moscone Center, San Francisco, CA)

About Nordic Nanovector ASA:

Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.

The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.

This information was brought to you by Cision http://news.cision.com

Contacts

Nordic Nanovector ASA
Luigi Costa
Chief Executive Officer
Cell: (+41) 79 124 8601
E-mail: lcosta@nordicnanovector.com
or
Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
Tel: (+47) 22 18 33 01
E-mail: tkvale@nordicnanovector.com

Contacts

Nordic Nanovector ASA
Luigi Costa
Chief Executive Officer
Cell: (+41) 79 124 8601
E-mail: lcosta@nordicnanovector.com
or
Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
Tel: (+47) 22 18 33 01
E-mail: tkvale@nordicnanovector.com